(IN BRIEF) Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm’s expertise in customized nucleic acids with Evonik’s advanced lipid and lipid nanoparticle (LNP) drug product development solutions. This collaboration aims … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged active ingredients, capping library screening, clinical trials, drug delivery, drug development, drug product development, enzymatic biotransformation, Evonik, Evonik capabilities, Fill & Finish, gene delivery, gene therapies, GMP manufacturing, Health Care Business, Kris S. Choi, life sciences sector, lipid nanoparticle, lipids, liposomes, LNP, mRNA development, mRNA-LNPs, North America manufacturing, nucleic acid medicines, nucleic acid therapeutics, nucleic acid therapies, Nutrition & Care division, oligonucleotides, partnership, pharmaceutical companies, RNA market, RNA therapeutics, siRNAs, small molecules, SmartCap® technology, South Korea, ST Pharm, strategic partnership, Yann d'Hervé
(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, has announced … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Spain
Tagged analytical development, Asklepios BioPharmaceutical, Bayer, Certified Good Manufacturing Practices (cGMP), commercial manufacturing, contract development and manufacturing organization (CDMO), European Medicines Agency (EMA), gene therapies, Javier García, Jimmy Vanhove, manufacturing capacity, quality control labs, recombinant adeno-associated virus (rAAV), science and technology (MSAT), single-use bioreactors, Spanish Agency for Medicines and Medical Devices (AEMPS), Viralgen Vector Core
(PRESS RELEASE) MELBOURNE, Australia, 3-Feb-2022 — /EuropaWire/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged AAVs, adeno-associated viral vectors, Arch Ventures, Australian technologist, Biotech, Codiak Biociences, Daisy Scarborough, DNA/RNA, Dr Ian Dixon, Evox Therapeutics, EVPS, Exopharm, Exoria, exosome therapeutics, exosomes, gene therapies, genetic disorders, LEAP™, lipid nanoparticles, LNPs, LOAD, Lonza, medicine, Pharmaceutical, vaccines
(PRESS RELEASE) GENEVA, 28-Oct-2021 — /EuropaWire/ — SGS, the world’s leading testing, inspection and certification company, has announced the expansion of its Glasgow biosafety testing facility thus helping to accelerate quality testing and reduce turnaround time for its clients. The … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Archie Lovatt, biological medicines, biologics, biologics manufacturers, biopharmaceutical, Biosafety Center of Excellence, BSL-2 cabinets, cell culture, cell therapies, COVID-19 vaccine, drug development, ELISA, gene therapies, Glasgow, Good Laboratory Practices, Good Manufacturing Practices, laboratories, monoclonal antibodies, polymerase chain reaction, real-time PCR testing, SGS, vaccines, virus detection
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?